Bio-Pharm

“The GLP-1 obesity treatment market is expected to grow to 100 trillion won( approximately 77…

A new treatment option for managing refractory blood cancer, specifically Diffuse Large B-Cell Lymphoma…

The management dispute within Hanmi Pharmaceutical Group that has heated up the pharmaceutical and biotech industry for…

HK Inno.N Corporation is emerging as a company to watch in the second half of the year, following strong performance and…

Celltrion has announced that their biosimilar Omvoh (CT-P39), a treatment for allergic asthma and chronic idiopathic…

Song Young-sook, chairwoman of Hanmi Pharm. Co., Ltd. has stepped down from the management of the company and said he…

The FDA approval of Eli Lilly's 'Donanemab' (marketed as Kisunla), the third Alzheimer's treatment globally, is…

ABL Bio has announced its ambition to become a global leader in the targeted cancer therapy market through the…

GC Biopharma announced on the 2nd that it has signed a contract with a major Pharmacy Benefit Manager (PBM) in…

Samsung Bioepis has announced that its biosimilar to Stelara, named ‘Pyzchiva’ (project name SB17, active ingredient…

Yuhan Corporation Receives Approval for Phase 1 Clinical Trial of Gaucher Disease Treatment Yuhan Corporation has…

A study demonstrating the superior efficacy of the combination therapy of Yuhan Corporation's non-small cell lung cancer…

Ahn Jae-Yong, CEO of SK Bioscience, highlighted the strategic importance of acquiring German contract manufacturing…